{"_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAoOaK3ckKDA","lastupdate":"2023-06-16T00:00:00.000Z","update_date":"2023-06-16T00:00:00.000Z","lastModified":"Mar 11, 2025","active":1,"confidence_score":100,"confidence_score_reason":"markets","urlname":"curesponse","minimal_profile":null,"status":"","fullstatus":"","acquired":0,"hide_reason":null,"hide_reason_data":null,"hide_reasons":[{"id":"8257rxn4P8EFQOmS5hAAauHyYMhhxrA5u6yWX4XUShpybX3AMNo3Y9","reason":"Pending approval - External entity"},{"id":"aOIaOiiqfpA8UMw6VCTh8ueRmkG3lzDy1NGqEOaJbe11OrCzMTCCd6","reason":"The company is a service provider"},{"id":"ddgjKuc3GgH8E5UehSVJviRl471BCajL1plO8HtGoOojy2NivYqQ7x","reason":"Owner asked to delete"},{"id":"EjOKM211H1ira9J63oaGPuUxvr7Oba55TZo3NWsFO5uhbNu7o4x4zD","reason":"The company is not Israeli"},{"id":"J7fQJtnT3GdWWSE3MD8rzaW65LJ4jEIKxSZnneQiReONdZjG3zIqWe","reason":"Owner asked to hide in the meantime"},{"id":"NxlAC3ReFb5ksiYNLp2FnUyluoJzwRCYfcF7xpTZaPM53SdWQ5kv0B","reason":"Pending approval"},{"id":"RhC1tlwXzioK0MfzBII3H2wepEfQOfKVktmdwqeqTJjGi3ZaBWUqZo","reason":"The company is not innovative"},{"id":"S0Ed46vNI6vZYVxLedANWGjas23K6hY0QdsCtiGYL7lshqIEdLV3sA","reason":"The company ceased operations in Israel"},{"id":"VTANq7bEvlsEcPjp0ghelXfShaCosgndONGjgU730aAOxXtaDIF5j3","reason":"This is a product of an existing company"}],"type":"Startup","logokey":"$laRokd2jpwkaoJA7T2GgU53gxdVZwScRdqDUu6FS6jjOS74720Hl0U","name":"Curesponse","oneliner":"Personalized Medicine for Accurate Cancer Treatment ","registrar":"515737328","website":"https://www.curesponse.com/","careerspage":"","founded_month":11,"founded_year":2017,"formernames":[],"sociallinks":{"twitter":"","youtube":"https://www.youtube.com/@curesponse/featured","facebook":"https://www.facebook.com/Curesponse","linkedin":"https://www.linkedin.com/company/18434992","instagram":""},"social":["https://www.facebook.com/Curesponse","https://www.linkedin.com/company/18434992","https://www.youtube.com/@curesponse/featured"],"flattenedsociallinks":"https://www.facebook.com/Curesponse|https://www.linkedin.com/company/18434992|https://www.youtube.com/@curesponse/featured","apps":{"appstore":"","googleplay":""},"is_claimed_by_owner":1,"employees":"11-50","employees_exact":18,"patent":1,"raised":14000000,"stage":"A","public_stage":"A","primary_sector_key":"agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","primary_sector":"Health Tech & Life Sciences","alternativenames":["Cu Response"],"about":"Curesponse’s technology represents the next step in personalized cancer medicine, advancing prediction capabilities beyond genomics to understand how cancer treatments will affect the patient’s tumor cells when they are in their native tumor.\n\nThe company developed cResponse, a test combined Genomic-Functional assay. The test starts with genomic profiling of the tumor to prioritize potential therapies. Then, together with additional therapies that were recommended by the patient’s oncologist, a short list of drugs and drug combinations is generated and functionally tested on the patient’s tumor.\n\nThe cResponse functional test preserves the original tumor composition (commonly referred to as the Tumor MicroEnvironment – TME) and its 3D structure to assess the effectiveness of all selected treatments on the tumor cells. This enables cResponse to empirically analyze the effectiveness of the recommended treatments following rapid genomic profiling with very high accuracy.","climatetech_description":null,"is_climatetech_relevant":null,"phone":"","country":null,"address":{"israeli":[{"id":"Ytp4LrKrhAdDO6fURSiuns4EippLJmCXtqb5K9h1aV0jfwHAozdl8d","city":"Rehovot","type":null,"address":"Rehovot, Israel","placeid":"ChIJj-W_kgW3AhURV_lYF8v4re4","notactive":null,"openeddate":null,"registrarid":null,"firstrdcenter":null,"registrarname":null}],"officesabroad":[{"id":"8d3b2661-be77-4380-b86c-22aba94c2531","city":null,"address":"3 Wimpole St, London, UK","country":"United Kingdom","placeid":null}]},"headquarter_address":null,"district":"Center District","news":[{"id":"m2IOfT19BjQMEH2HqR9Bh9cp09WzZj6o1JXhz1McUxzo6DJNDAbOri","date":"May 9, 2023","link":"https://www.accesswire.com/753718/Curesponse-Presents-Positive-Preliminary-Clinical-Results-from-a-Multi-Center-UK-Study-at-the-AACR-Meeting-in-Orlando-Florida","source":"www.accesswire.com","visible":1,"analysis":{"tags":"precision oncology","company":"Curesponse","layoffs":null,"summary":"Curesponse, a precision oncology company, presented preliminary clinical results from a UK Study at the AACR meeting. The study demonstrated the predictive power of their cResponse platform in determining patient response to cancer therapeutics. The results showed a 96.5% sensitivity and 90% specificity across various solid cancer types. Curesponse plans to make the technology available for cancer patients in the UK and EU in 2023, and in the USA in 2024. The cResponse platform combines next-generation sequencing with a functional assay to assess the response of cancerous tissue to different drugs. It is the first personalized cancer platform that offers an empirical test within 2 weeks from biopsy.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["cResponse platform","UK Study","predictive power","oncology therapeutics","expansion"],"date_of_event":"May 9, 2023","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers","Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Customers  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"ny8lHBPVSaJpPVDOeRxNs4SBJXVVCiEu5iZpck8DJx36UfP1V4zFRQ","news_summary":"Curesponse Presents Positive Preliminary Clinical Results from a Multi-Center UK Study at the AACR Meeting in Orlando, Florida","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"b2G6JubxFctbcal2mJcj2AVa8Zz2besaxBgJk7gGCpCGCwSpxFOinc","date":"Feb 23, 2023","link":"https://www.prnewswire.com/news-releases/curesponse-announces-clalit-health-services-largest-israeli-hmo-to-provide-commercial-coverage-for-the-cresponse-test-301753092.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"precision oncology","company":"Curesponse","layoffs":null,"summary":"Curesponse, a precision oncology company, announces that Clalit HMO has decided to include cResponse in its Oncology Services package for premium supplementary insurance members. The cResponse platform combines next-generation sequencing with a functional assay to assess the response of cancerous tissue to different drugs and drug combinations. Clalit Health Services, the worlds second-largest HMO, will now offer the cResponse assay to its members, expanding access to the technology for millions of cancer patients. This decision is seen as a recognition of the benefits the cResponse platform offers oncologists and patients in personalized cancer treatment selection.","partners":null,"customers":"Clalit HMO","investors":null,"confidence":8,"key_topics":["cResponse","Clalit HMO","oncology services","Mushlam Platinum","functional-genomics oncology drug prioritization technology"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"PLy57JF6u3p80mDuMFtlVbVw1sPmIONNdky8cp7NUqPoyMBr1Dq8Jk","news_summary":"Curesponse Announces Clalit Health Services, Largest Israeli HMO, to Provide Commercial Coverage for the cResponse™ test","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"Y4qv8DfOoX8Z4LRqZlyHidtDc0pV50rO0CPAt6nzf4xgFFPY2fLuZY","date":"Dec 21, 2022","link":"https://www.prnewswire.com/news-releases/curesponse-shows-applicability-of-next-generation-immuno-oncology-drugs-in-the-pan-cancer-cresponse-system-301708224.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"immuno-oncology, cancer, drug development","company":"Curesponse","layoffs":null,"summary":"Curesponse, a precision oncology start-up, presented results at the ESMO Immuno-Oncology Congress demonstrating the application of their cResponse platform for modeling and evaluating immune modulating drugs in cancer tissue. The platform combines next-generation sequencing with a functional assay to assess the response of cancerous tissue to different drugs and drug combinations. The data presented showed the activation of T-cells and recruitment of immune cells in colorectal, lung, and pancreatic cancer. The cResponse platform has been utilized by cancer researchers and pharmaceutical companies and will be offered to cancer patients in the UK, EU, and USA in the coming years. The company is collaborating with leading pharma partners and the test is CE marked and reimbursed by private payers in Israel.","partners":"leading pharma partners","customers":null,"investors":null,"confidence":8,"key_topics":["cResponse platform","Immuno-oncology","Functional-genomics","Drug prioritization","Tumor Microenvironment"],"date_of_event":"H1 2023","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers","Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Customers  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"ifs6eelbYvBygjQM4D6UYmnS0JmYIoLxum4shGrZ6Y5MraRFjr6z71","news_summary":"Curesponse shows applicability of next generation Immuno-oncology drugs in the pan-cancer cResponse system","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"yN37rWBaANT6VltHLoXNZiRyfnCeIhjkbN6uWg5X7lFzsUHczlapkJ","date":"Nov 15, 2021","link":"https://www.globenewswire.com/en/news-release/2021/11/15/2334630/0/en/Curesponse-Secures-Additional-USD-8-Million-Funding-for-Its-Breakthrough-Precision-Oncology-Platform.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":"precision oncology","company":"Curesponse","layoffs":null,"summary":"Curesponse, a cancer precision medicine company, has secured an additional USD 8 million funding for its breakthrough precision oncology platform. The funding will be used to scale clinical studies and expand the companys international footprint. Curesponses platform, cResponse, accurately predicts a patients response to cancer treatment by combining rapid genomic sequencing with a 3D functional assay. The platform takes into account tumor-microenvironment interactions and cancer tissue architecture, providing critical and actionable information for clinicians and patients. Recent clinical studies have shown that Curesponses technology predicts the patients clinical response with high specificity and sensitivity. The company aims to meet the increasing demand for personalized treatment in the precision medicine market.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["Cancer precision medicine","cResponse platform","Tumor microenvironment interactions","Clinical studies","Precision medicine market"],"date_of_event":"2021-11-15","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$8 million","structured_issues":["Investment","Expand"],"acquisition_amount":null,"structuredIssuesShow":"#Investment  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"WKFCUH4KtVgCCyTKz9G0iwPaHPiILYI0zhNA6QEvXJ9UEdpoGEc5uh","news_summary":"Curesponse Secures Additional USD 8 Million Funding for Its Breakthrough Precision Oncology Platform","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"f638e174-b95b-4d31-bdda-4907080f2f5c","date":"Jun 5, 2020","link":"https://www.prnewswire.com/news-releases/curesponse-secures-6m-series-a-for-breakthrough-precision-medicine-301071319.html","source":"www.prnewswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"VSzU1kEqlvECqSNGDNLoLpdtpjMNkZu7Njm2nsHkQfq4iHGPvjfvvH","news_summary":"https://www.prnewswire.com/news-releases/curesponse-secures-6m-series-a-for-breakthrough-precision-medicine-301071319.html","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"}],"newsNumber":5,"techcommunityinvolvement":null,"mediagallery":[{"id":"JsqN07eKPNHLpybc1hBKqy0gUphIz3OPHmdKQMtHdl7aSdiQ0vtqTS","timestamp":"2023-06-16 19:37:16.000000","resources_type":2,"resources_title":"","resources_file_name":"ICfWlEAkOw8","alt":"","imageurl":"https://img.youtube.com/vi/ICfWlEAkOw8/0.jpg","url":"http://youtu.be/ICfWlEAkOw8"}],"tags":["clinical-trials","personalized-medicine","cancer-diagnostics","pharmaceuticals","genetics","diagnostics","oncology","cancer","patients","3d-technology","pharma-companies","bioconvergence"],"classificationIDs":["agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IexkcoIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NvztpMKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA"],"technologysuccessstory":[{"date":"2017-11-01","name":"3 dimensional tissue culture system for modeling cancer growth and drug response","tags":["cancer-diagnostics","cancer","3d-technology"],"category":"Pharmaceuticals & Diagnostics","tto_logo":"/image_cloud/yeda_tto_logo_fbd2f2eb-6016-11e8-8318-41fdcbb0dda6","university_logo":"/image_cloud/yeda_institution_logo_fbd2f2eb-6016-11e8-8318-41fdcbb0dda6"}],"usecases":[],"businessmodels":["B2B","B2C"],"productstage":"Clinical Trial","products":["cResponse"],"geomarkets":[],"targetmarkets":[],"marketcapital":null,"marketcapitaldate":null,"funding":{"investors":3,"lastfunding":"$8M","totalrounds":2,"fundingstage":"A","totalfunding":"$14M","publicinvestors":3,"lastpublicfunding":8000000,"totalpublicrounds":2,"totalpublicfunding":14000000},"team":[{"name":"Guy Neev","email":"guyneev@curesponse.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoImrxYUJDA","bounced":true,"claimed":0,"founder":1,"urlname":"guy-neev-3","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICgybCWygoM","position":"Co-founder & CEO","last_name":"Neev","claimtoken":"FpFkLI7qE9R0SuBjapyYuflWzA668UXzH8L0KOiMYxpjhBfcgRIc1l","first_name":"Guy","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/guy-neev-6136504/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2025-03-11 15:48:05.000000","initials":"GN","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Seth Salpeter","email":"seth.salpeter@gmail.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoMmUzvIKDA","bounced":false,"claimed":1,"founder":1,"urlname":"seth-salpeter-1","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICg5vmq3wkM","position":"Co-founder & CTO","last_name":"Salpeter","claimtoken":"2fc6f7a247c95e584b271e35443b8bef51e9e807c106eda463dec7d0ad49a9ba","first_name":"Seth","picturekey":"$Lsct9OBMGD7OdoUU8xBzl0tkcvYETONDGoXVvON2lsNvJh8yZPWirX","claimeddate":"2018-05-07","linkedinurl":"https://www.linkedin.com/in/seth-salpeter-6021741b","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2018-05-07 15:01:02.000000","initials":"","pictureurl":"https://storage.googleapis.com/clean-finder-353810/$Lsct9OBMGD7OdoUU8xBzl0tkcvYETONDGoXVvON2lsNvJh8yZPWirX","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Vered  Bar","email":"vered@curesponse.tech","phone":"","gender":"Female","userid":"L6TNWdxbytpfU8bW3e1fHnYQxi1DCWBBg8fwFq2c1oMHA4Ji1iqeLU","bounced":false,"claimed":1,"founder":0,"urlname":"vered-bar","visible":1,"memberid":"eoPHu4s7070ypI647Rh7TdsagZPc1NqetcPo7lY73vDy8z2qneUdKD","position":"VP R&D","last_name":"Bar","claimtoken":"uaPaahSC27pG0LUSSAwAa0LstMqH66ftGe7FAMhi43sHtjCNdYoaAV","first_name":"Vered ","picturekey":"$i1TJDKyMYMVHd28Z4cw3Z0xH8onKgzKvRPS57d6hJbQ03DilSe2Txl.jpeg","claimeddate":"2024-05-28","linkedinurl":"https://www.linkedin.com/in/vered-bar-28b24a34/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2024-05-28 12:25:28.000000","initials":"","pictureurl":"https://storage.googleapis.com/clean-finder-353810/$i1TJDKyMYMVHd28Z4cw3Z0xH8onKgzKvRPS57d6hJbQ03DilSe2Txl.jpeg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""}],"description_edited":1,"tag_line_edited":1,"sector":"Life Sciences & HealthTech","sectorverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgPGylJ0IDA","fullname":"Natalia Golczar"},"biverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgMGgoMMJDA","fullname":"Yanina Wainscheinker"},"biverifydate":"2020-06-09T00:00:00.000Z","crunchbaseid":"curesponse","lastupdator":"Yanina Wainscheinker","lastupdator_email":"yanina.wainscheinker@sncentral.org","creator":"Jenny Sotnik-Talisman","creator_email":"genys30@yahoo.com","createdate":"2018-01-02T00:00:00.000Z","biverification":"Yanina Wainscheinker","sectorverification":"Natalia Golczar","affiliatedOrganizations":null,"timeline":[{"id":"qbHJM7bir3qW9ff5ZB6m1rAZDLf8x5TchIcqGd79alQfa7vGwYpxeq","hub":"BeyondBio SCALE","date":"Dec 2022","batch":"3","amount":"Undisclosed","hub_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4KarzuIKDA","source":"https://www.calcalistech.com/ctechnews/article/sjpshqhdj","enddate":"Aug 2023","hub_type":"Corporate Accelerator","eventtype":"GraduationEvent","hub_hidden":false,"investment":[],"hub_fullurl":"/program_page/beyondbio-scale","hub_logokey":"$GKQys2ISctzGq4yatr4EcHcNR7XHE0b24C47VOPM2pB8FpW4zM9QbS","hub_urlname":"/program_page/beyondbio-scale","eventvisibility":null,"amountvisibility":null,"fundingvisibility":null,"style":"","hiddenCompanyTooltip":"","hub_logourl":"https://storage.googleapis.com/clean-finder-353810/$GKQys2ISctzGq4yatr4EcHcNR7XHE0b24C47VOPM2pB8FpW4zM9QbS","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"R3UynhJzVdenUAi2CeNa9ZykiZthQwL0aMRuT31d6RWB9b5BzqywSt","date":"Nov 2021","amount":"$8M","source":"https://www.globenewswire.com/en/news-release/2021/11/15/2334630/0/en/Curesponse-Secures-Additional-USD-8-Million-Funding-for-Its-Breakthrough-Precision-Oncology-Platform.html","eventtype":"FundingRoundEvent","investment":[{"name":"Undisclosed Investor(s)","type":"Investor","amount":null,"hidden":false,"country":"Europe","fullurl":"/investor_page/undisclosed-investor-s","logokey":null,"tagline":"","urlname":"/investor_page/undisclosed-investor-s","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCE3L3CCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"pzwG7gKi3Rg7BQ80E4hQi6UhZT4BcTx64ea9VaoKXRnayqWsGWC2H3","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Undisclosed Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":8000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCEvNCOCww","date":"Jun 2020","amount":"$6M","source":"https://www.prnewswire.com/news-releases/curesponse-secures-6m-series-a-for-breakthrough-precision-medicine-301071319.html","eventtype":"FundingRoundEvent","investment":[{"name":"aMoon Fund","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/amoon-partners","logokey":"$XFAsLr4oM0cpGPl8KooBiRDedzqYg8XejD5EGeDP9vLvSOQjBic7lH","tagline":null,"urlname":"/investor_page/amoon-partners","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAoIj37p8KDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"4c9cN8FtjAtc8kJEnS8kUra1gMTBcNMDxk1UIWAiJXB7ObjSZRDmrq","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$XFAsLr4oM0cpGPl8KooBiRDedzqYg8XejD5EGeDP9vLvSOQjBic7lH","leadcaption":"","followupcaption":""},{"name":"NCL Technology Ventures","type":"Investor","amount":0,"hidden":false,"country":"United Kingdom","fullurl":"/investor_page/ncl-technology-ventures","logokey":"$WPV1uJImCPiLwul2JndoYKi77VQkTTtKkBEHfEpiXHclbycScQz6WX","tagline":"","urlname":"/investor_page/ncl-technology-ventures","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOC-sf-JCww","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"q3SRGanR54gp4CxoqesgyevspSB612bmo98pYpKFE3rPcLq9ni2HGV","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":null,"isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":null,"leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$WPV1uJImCPiLwul2JndoYKi77VQkTTtKkBEHfEpiXHclbycScQz6WX","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"A Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":6000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"investmentstage":[],"exits":[],"investments":[],"portfolio":[],"funds":[],"founded":"11/2017","databases":[],"sharedspaces":[],"utilities":[],"contributors":[],"employeesworldwide":"","fundingtype":"Startup","parsedName":"Curesponse","logourl":"https://storage.googleapis.com/clean-finder-353810/$laRokd2jpwkaoJA7T2GgU53gxdVZwScRdqDUu6FS6jjOS74720Hl0U","oglogourl":"https://storage.googleapis.com/clean-finder-353810/$laRokd2jpwkaoJA7T2GgU53gxdVZwScRdqDUu6FS6jjOS74720Hl0U","seoabout":"Curesponse’s technology represents the next step in personalized cancer medicine, advancing prediction capabilities beyond genomics to understand how cance...","seoTitle":"Israeli Startup","solutions":[],"teamMembersNumber":3,"primarySector":"Health Tech & Life Sciences","primary-sector-display":"block","classifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Test Diagnostics & Screening","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IexkcoIDA","classificationName":"sectorclassification"},{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"},{"depth":2,"name":"Genes","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NvztpMKDA","classificationName":"coretechnology"},{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"}],"classificationDelimited":["SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA>Test Diagnostics & Screening#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IexkcoIDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA>Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA>Genes#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NvztpMKDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA"],"classificationsViewModel":"|0:>SectorClassificationModel|1:>SectorClassificationModel/Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA|2:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA/Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA/Test Diagnostics & Screening#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IexkcoIDA|0:>IndustryClassificationModel|1:>IndustryClassificationModel/Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA/Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA|0:>TechnologyClassificationModel|1:>TechnologyClassificationModel/Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA|2:>TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA/Genes#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NvztpMKDA|","classificationTrees":{"sector":[{"title":"Health Tech & Life Sciences","key":"0-0","path":"SectorClassificationModel>Health Tech & Life Sciences","children":[{"title":"Pharma & Medical Biotechnology","key":"0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology","children":[{"title":"Test Diagnostics & Screening","key":"0-0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology>Test Diagnostics & Screening"}]}]}],"targetCustomer":[{"title":"Healthcare & Life Sciences","key":"0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences","children":[{"title":"Life Sciences","key":"0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences","children":[{"title":"Pharmaceuticals","key":"0-0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences>Pharmaceuticals"}]}]}],"coreTechnology":[{"title":"Biologicals","key":"0-0","path":"TechnologyClassificationModel>Biologicals","children":[{"title":"Genes","key":"0-0-0","path":"TechnologyClassificationModel>Biologicals>Genes"}]}]},"sectorClassifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Test Diagnostics & Screening","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IexkcoIDA","classificationName":"sectorclassification"}],"coreTechnologyClassifications":[{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"},{"depth":2,"name":"Genes","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NvztpMKDA","classificationName":"coretechnology"}],"targetCustomerClassifications":[{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"}],"classificationNames":{"sector":["Health Tech & Life Sciences","Pharma & Medical Biotechnology","Test Diagnostics & Screening"],"coreTechnology":["Biologicals","Genes"],"targetCustomer":["Healthcare & Life Sciences","Life Sciences","Pharmaceuticals"]},"section":null,"sectionParams":"","queryParams":"","popup_claim_profile":"false","claimedBadge":"inline","display":{"mainContact":"none","climateTag":"none","seeMoreSimilarCompanisDisplay":"none","similarCompaniesTitleFontSize":"3.2rem","similarCompaniesTitle":"Similar Companies","similar_companies":[]},"mainContact":{},"_eventview":{"publicoffering_exit":[],"privateequityfunding":[{"id":"R3UynhJzVdenUAi2CeNa9ZykiZthQwL0aMRuT31d6RWB9b5BzqywSt","date":"Nov 2021","amount":"$8M","source":"https://www.globenewswire.com/en/news-release/2021/11/15/2334630/0/en/Curesponse-Secures-Additional-USD-8-Million-Funding-for-Its-Breakthrough-Precision-Oncology-Platform.html","eventtype":"FundingRoundEvent","investment":[{"name":"Undisclosed Investor(s)","type":"Investor","amount":null,"hidden":false,"country":"Europe","fullurl":"/investor_page/undisclosed-investor-s","logokey":null,"tagline":"","urlname":"/investor_page/undisclosed-investor-s","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCE3L3CCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"pzwG7gKi3Rg7BQ80E4hQi6UhZT4BcTx64ea9VaoKXRnayqWsGWC2H3","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Undisclosed Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":8000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCEvNCOCww","date":"Jun 2020","amount":"$6M","source":"https://www.prnewswire.com/news-releases/curesponse-secures-6m-series-a-for-breakthrough-precision-medicine-301071319.html","eventtype":"FundingRoundEvent","investment":[{"name":"aMoon Fund","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/amoon-partners","logokey":"$XFAsLr4oM0cpGPl8KooBiRDedzqYg8XejD5EGeDP9vLvSOQjBic7lH","tagline":null,"urlname":"/investor_page/amoon-partners","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAoIj37p8KDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"4c9cN8FtjAtc8kJEnS8kUra1gMTBcNMDxk1UIWAiJXB7ObjSZRDmrq","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$XFAsLr4oM0cpGPl8KooBiRDedzqYg8XejD5EGeDP9vLvSOQjBic7lH","leadcaption":"","followupcaption":""},{"name":"NCL Technology Ventures","type":"Investor","amount":0,"hidden":false,"country":"United Kingdom","fullurl":"/investor_page/ncl-technology-ventures","logokey":"$WPV1uJImCPiLwul2JndoYKi77VQkTTtKkBEHfEpiXHclbycScQz6WX","tagline":"","urlname":"/investor_page/ncl-technology-ventures","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOC-sf-JCww","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"q3SRGanR54gp4CxoqesgyevspSB612bmo98pYpKFE3rPcLq9ni2HGV","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":null,"isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":null,"leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$WPV1uJImCPiLwul2JndoYKi77VQkTTtKkBEHfEpiXHclbycScQz6WX","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"A Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":6000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"nonequityfunding":[],"merger_acquisitions":[],"others":[]}}